Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting
The Journal of Allergy and Clinical Immunology: In Practice · 2025-01 · 13 (1) · 121-131
DOI: 10.1016/j.jaip.2024.09.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025-01. Verfasst von Sylvia H Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophilia, Asthma, Sinusitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Dupilumab has been used with significant benefit in the treatment of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Phase 3 clinical trials have demonstrated transient eosinophilia and rare eosinophil-related and other adverse effects. OBJECTIVE: To characterize dupilumab-associated eosinophilia (absolute eosinophil count ≥1.5 × 103/μL within 36 weeks of dupilumab initiation) and adverse effects associated in real-world patients with asthma and CRSwNP in the United States. METHODS: Retrospective chart review of 251 patients receiving dupilumab for asthma and/or CRSwNP seen at a single institution. RESULTS: Among the 142 patients who had absolute eosinophil counts checked before and after treatment, 16 (11.3%) had posttreatment eosinophilia, including 11 (7.7%) who had new eosinophilia on dupilumab initiation. Thirteen patients with posttreatment eosinophilia remained on dupilumab, 10 of whom had resolution of eosinophilia. Eosinophil-related adverse effects were rare, and cases of eosinophilic granulomatous polyangiitis were limited to one patient with eosinophilia and one patient with normal eosinophil levels who was receiving systemic corticosteroids. Other adverse effects included arthralgias (13 of 251; 5.2%), rash (8 of 251; 3.2%), and conjunctivitis (7 of 251; 2.8%). All patients with pretreatment eosinophilia and most patients with posttreatment eosinophilia received significant treatment benefit for the respiratory disease with dupilumab. CONCLUSIONS: Whereas dupilumab-associated eosinophilia is seen in a subset of patients, persistent eosinophilia or eosinophil-related adverse effects are rare. Furthermore, treatment benefit with dupilumab despite eosinophilia supports its continued use in both asthma and CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Ill.
- Northwestern Medicine Enterprise Data Warehouse, Feinberg School of Medicine, Northwestern University, Chicago, Ill.
- Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: anjupeters@northwestern.edu.
Förderung
- NIAID NIH HHS
Zitieren
APA
Li, S. H., Nehme, K. F., Moshkovich, A., Suh, L., Pawlowski, A., Ali, Y., Patel, G. B., Kuang, F. L., & Peters, A. T. (2025). Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting. The Journal of Allergy and Clinical Immunology: In Practice, 13(1), 121-131. https://doi.org/10.1016/j.jaip.2024.09.013
Vancouver
Li SH, Nehme KF, Moshkovich A, Suh L, Pawlowski A, Ali Y, et al. Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13(1):121-131. doi:10.1016/j.jaip.2024.09.013
BibTeX
@article{Li2025,
author = {Li, Sylvia H and Nehme, Katharine Foster and Moshkovich, Anna and Suh, Lydia and Pawlowski, Anna and Ali, Yasmeen and Patel, Gayatri B and Kuang, Fei Li and Peters, Anju T},
title = {Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
volume = {13},
number = {1},
pages = {121--131},
doi = {10.1016/j.jaip.2024.09.013}
}
EUVIMED